Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

CGEM Cullinan Therapeutics Inc

23,50

0,71 (3,12%)

01 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form ARS - Annual Report to Security Holders

Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Cullinan Therapeutics Charts.

Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Cullinan Therapeutics Charts.

News Cullinan Therapeutics Inc

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Freitag 24 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 23 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Donnerstag 23 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Donnerstag 16 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Donnerstag 16 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Donnerstag 16 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Donnerstag 16 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Mittwoch 15 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 9 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 6 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Montag 29 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Mittwoch 24 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere Cullinan Therapeutics Inc News-Artikel

SG Issuer Sgi Zc Dec28 Eur

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen